Stock Watch: The Pandemic Brings Christmas Presents
Analyst Upgrades And Deferrals of Drug Pricing Legislation May Appear As Year-End Gifts
Executive Summary
While the Omicron variant does not bode well for 2022, vaccine boosters and oral antivirals are the products from the pharmaceutical sector that should keep on giving. Even if partisan analysts choose to forget them.
You may also be interested in...
Pfizer Confirms Paxlovid’s High Efficacy And Reassures On Omicron
While Merck & Co’s Lagevrio’s results declined after an interim readout, Pfizer’s oral COVID-19 candidate Paxlovid has maintained its strong performance in protecting high-risk patients from hospitalization or death.
Rebate Reprieve For Generics And Biosimilars Added To Build Back Better Act
The Build Back Better Act has been updated to exempt generics experiencing or at risk of shortage from its planned inflation rebates, as well as biosimilars. But the US Association for Accessible Medicines has called for further changes to the proposed bill to protect off-patent drugs.
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.